JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/45/0.1/21.11.25 | Delayed Börse Stuttgart 07:23:38 2024-07-17 am EDT | ||
| 0.39 EUR | +2.63% |
|
| Current month | -11.63% | ||
| 1 month | -2.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.39 | +2.63% |
| 24-07-16 | 0.38 | +2.70% |
| 24-07-15 | 0.37 | -2.63% |
| 24-07-12 | 0.38 | -2.56% |
| 24-07-11 | 0.39 | +2.63% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 07:23 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK8V4L |
| ISIN | DE000JK8V4L0 |
| Date issued | 2024-04-29 |
| Strike | 45 $ |
| Maturity | 2025-11-21 (492 Days) |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.34 € |
| Spread | 0.01 € |
| Spread % | 2.50% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
51.69
USD
Spread / Average Target
+25.47%
- Stock Market
- Warrants
- Warrant
